Millipore and Proteome Sciences Announce Licensing Agreement
Millipore Corporation and Proteome Sciences plc announced they have signed an exclusive license agreement to develop new products that will help to advance the study of Alzheimer’s disease. Under the terms of the agreement, Millipore will develop Luminex bead-based multiplex immunoassays to measure Proteome Sciences’ proprietary Alzheimer’s disease biomarkers. The ability to quickly test for these biomarkers will enable researchers to develop new drugs and diagnostics to treat and monitor patients with Alzheimer’s.
Proteome Sciences has established a strong portfolio of patent-protected blood biomarkers of Alzheimer’s disease working in collaboration with the Institute of Psychiatry (IoP) at King’s College London. A number of these biomarkers have been independently identified and their relationship to Alzheimer’s disease confirmed by researchers at GlaxoSmithKline.
Millipore will acquire the exclusive right to develop and sell Luminex bead-based panels for research related to the study of Alzheimer’s disease and other cognitive function disorders. Proteome Sciences retains all rights to clinical applications of these biomarkers. Financial terms of the license agreement were not disclosed.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.